Confirming the significant role of CTLA-4 signaling in the immunosuppression of cancer patients, the blockage of this molecule in clinical settings by monoclonal antibodies has been able to improve significantly the survival of metastatic melanoma patients [96, 97]. This evidence concerns the gene CTLA4 and cancer.